Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Cerilliant
Colorcon
Baxter
Johnson and Johnson
Chinese Patent Office
Medtronic
Argus Health
Queensland Health

Generated: December 11, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ERTUGLIFLOZIN

« Back to Dashboard

Clinical Trials for Ertugliflozin

Trial ID Title Status Sponsor Phase Summary
NCT00989079 A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036) Completed Pfizer Phase 1 Ertugliflozin (PF-04971729, MK-8835) is a new compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this study is to evaluate the safety and tolerability along with the pharmacokinetics of single escalating doses of ertugliflozin under fed and fasted conditions in healthy volunteers.
NCT00989079 A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036) Completed Merck Sharp & Dohme Corp. Phase 1 Ertugliflozin (PF-04971729, MK-8835) is a new compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this study is to evaluate the safety and tolerability along with the pharmacokinetics of single escalating doses of ertugliflozin under fed and fasted conditions in healthy volunteers.
NCT01018823 A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037) Completed Pfizer Phase 1 Ertugliflozin (PF-04971729, MK-8835) is under development for the treatment of Type 2 Diabetes. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, of multiple oral doses of ertugliflozin.
NCT01018823 A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037) Completed Merck Sharp & Dohme Corp. Phase 1 Ertugliflozin (PF-04971729, MK-8835) is under development for the treatment of Type 2 Diabetes. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, of multiple oral doses of ertugliflozin.
NCT01054300 Effects Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040) Completed Pfizer Phase 1 This is a Phase 1 pharmacokinetic, pharmacodynamic study to understand the manner in which the body responds to, as well as how the drug is handled by the body, with once vs twice daily dosing of ertugliflozin (PF-04971729, MK-8835) in participants with type 2 diabetes.
NCT01054300 Effects Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040) Completed Merck Sharp & Dohme Corp. Phase 1 This is a Phase 1 pharmacokinetic, pharmacodynamic study to understand the manner in which the body responds to, as well as how the drug is handled by the body, with once vs twice daily dosing of ertugliflozin (PF-04971729, MK-8835) in participants with type 2 diabetes.
NCT01059825 Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016) Completed Pfizer Phase 2 MK-8835-016 (B1521006) is designed to evaluate the safety and efficacy of an investigational drug, ertugliflozin (MK-8835, PF-04971729) in participants with Type 2 diabetes mellitus. Participants in the study will receive 1 of 6 treatments for 12 weeks including 1 treatment with an approved drug (sitagliptin) for the treatment of Type 2 diabetes mellitus.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Ertugliflozin

Condition Name

Condition Name for Ertugliflozin
Intervention Trials
Type 2 Diabetes Mellitus 14
Diabetes Mellitus, Type 2 4
Heart Failure 2
Adult 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ertugliflozin
Intervention Trials
Diabetes Mellitus, Type 2 20
Diabetes Mellitus 20
Heart Failure 2
Kidney Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ertugliflozin

Trials by Country

Trials by Country for Ertugliflozin
Location Trials
United States 32
Bulgaria 1
Czech Republic 1
United Kingdom 1
Argentina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ertugliflozin
Location Trials
Virginia 1
Maine 1
Wisconsin 1
Alabama 1
Arizona 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ertugliflozin

Clinical Trial Phase

Clinical Trial Phase for Ertugliflozin
Clinical Trial Phase Trials
Phase 3 10
Phase 2 3
Phase 1 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ertugliflozin
Clinical Trial Phase Trials
Completed 16
Active, not recruiting 2
Not yet recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ertugliflozin

Sponsor Name

Sponsor Name for Ertugliflozin
Sponsor Trials
Merck Sharp & Dohme Corp. 21
Pfizer 20
University Health Network, Toronto 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ertugliflozin
Sponsor Trials
Industry 42
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Covington
Mallinckrodt
Medtronic
Moodys
Healthtrust
Baxter
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.